Chronic thromboembolic pulmonary hypertension
MONDO:0013024Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by the persistence of thromboemboli in the form of organized tissue obstructing the pulmonary arteries. The consequence is an increase in pulmonary vascular resistance (PVR) resulting in pulmonary hypertension (PH) and progressive right heart failure.
Also known as: CTEPH, Cteph, Dvt-negative, susceptibility to, pulmonary hypertension, chronic thromboembolic, without deep vein thrombosis, susceptibility to
59 clinical trials for this condition and its sub-types, 41 tagged with Chronic thromboembolic pulmonary hypertension itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New combo therapy aims to ease strain on heart in rare lung condition
Disease control Stopped earlyThis study tests whether combining two medications (Riociguat and Macitentan) with a balloon procedure to open blocked lung arteries can improve heart function in people with chronic thromboembolic pulmonary hypertension (CTEPH). The trial enrolls 15 adults who cannot have surger…
Phase 3 • Sponsor: Dr Sudarshan Rajagopal • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Heart drug study halted early: limited data on right heart changes
Disease control Stopped earlyThis study looked at whether the drug riociguat could improve right heart size and function in people with two types of pulmonary hypertension (PAH and CTEPH). It planned to enroll 30 adults, but was terminated early, so results are limited. The goal was to use echocardiograms to…
Phase 4 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC